J&J/Veridex’ CellSearch System Paves Way For FDA Class II Designation
This article was originally published in The Gray Sheet
Executive Summary
FDA formally classifies immunomagnetic circulating cancer cell selection and enumeration systems as Class II with special controls in a May 11 final rule
You may also be interested in...
Immunicon IPO Proceeds To Support FDA Clearance Of Cancer Diagnostics
Johnson & Johnson/Veridex will stand to benefit from Immunicon's proposed $70.9 mil. IPO under the terms of the companies' exclusive development, licensing and marketing agreement for cancer diagnostics
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.